Press Releases
Toronto, Ontario--(Newsfile Corp. - May 23, 2024) - Deveron Corp. (TSXV: FARM) ("Deveron" or the "Company"), a leading agriculture service and data company in North America, is pleased to announce that the Company's Q3 financial results will be released after market close on Tuesday May 28th, 2024. At that time, the financial results and related documents will be posted on SEDAR Plus and Deveron's financials web page at https://deveron.com/financials.
Deveron will hold... (continue reading...)
Toronto, Ontario--(Newsfile Corp. - May 23, 2024) - Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) ("Aurania" or the "Company") announces it has closed the second tranche (the "Second Tranche") of its non-brokered private placement of up to 20,000,000 units ("Units") for aggregate gross proceeds of up to C$4,000,000, subject to the right of the Company to increase the size of the Initial Offering by up to 25% (the "Offering"). An aggregate of 4,219,752... (continue reading...)
State-of-the-Art Pivozon EA Revolutionizes EURUSD Trading with Advanced Technical Indicators and Robust Risk Management
Dubai, United Arab Emirates, 23rd May 2024 - Avenix Fzco is thrilled to announce the launch of its latest innovation, the Pivozon Expert Advisor (EA), a sophisticated forex robot specifically designed for the EURUSD currency pair on the D1 timeframe. This new tool leverages advanced technical indicators... (continue reading...)
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of abstracts on alisertib to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting will be held at McCormick Place in Chicago and online from May 31-June 4.
Full abstracts of the following posters are available online at https://conferences.asco.org/am/abstracts.
- Abstract 1037:... (continue reading...)
Advancing oncology and bridging healthcare gaps
NEW YORK--(BUSINESS WIRE)-- Flatiron Health today announced its significant presence at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago this June. Nine abstracts led by Flatiron have been accepted for poster presentation and online publication. A comprehensive of all accepted research using Flatiron data is available via ASCO's website.
Aligned with the conference... (continue reading...)
More Press Releases
View Older Stories-
PARAMOUNT GLOBAL AND CHARTER COMMUNICATIONS ANNOUNCE NEW MULTI-YEAR AGREEMENT FOR DISTRIBUTION OF PARAMOUNT'S LINEAR NETWORKS, CBS OWNED-AND-OPERATED STATIONS AND DIRECT-TO-CONSUMER STREAMING SERVICES
-
NW Natural Holdings and NW Natural CEO David H. Anderson Announces Retirement
-
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
SILVERCORP REPORTS ADJUSTED NET INCOME OF $39.3 MILLION, $0.22 PER SHARE, AND CASH FLOW FROM OPERATIONS OF $91.6 MILLION FOR FISCAL 2024
-
Nimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual Meeting
-
Special Olympics Florida and Orlando Health Announce Five-Year Partnership
-
Extraordinary 80+ Acre Paradise Island, Boca Grande, FL, Hits Market After 70-Years: A Once-in-a-Lifetime Opportunity for Discerning Buyers
-
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101
-
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
-
Barnes & Noble Education Announces Preliminary Fiscal Year 2024 Results
-
Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients
-
KinderCare Learning Companies Applauds Bipartisan Effort to Support Working Families through Child Care Access
-
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
-
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
-
EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001, at the Upcoming 2024 ASCO Annual Meeting
-
Landmark Study from Mercy BioAnalytics and University College London Demonstrates Significant Improvement Over CA125 and Ultrasound for Ovarian Cancer Screening
-
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (m
-
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
-
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Ann
-
ALIMENTATION COUCHE-TARD TO RELEASE RESULTS FOR ITS FOURTH QUARTER AND FISCAL YEAR 2024 ON JUNE 25, 2024
-
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel
-
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma
-
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the
-
Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting
-
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
-
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
-
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting
-
TelevisaUnivision Announces Pricing of $1.0 Billion Debt
-
Elcora Announces Share Consolidation
-
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinica
-
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
-
BNY Mellon Alcentra Global Multi-Strategy Credit Fund, Inc. Declares Distribution
-
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
-
White House National Cyber Director Coker Discusses Cybersecurity Implementation Plan 2.0 at Conference Hosted by McCrary Institute for Cyber & Critical Infrastructure Security
-
KBRA Assigns AAA Rating, Stable Outlook to the New Mexico Finance Authority State Transportation Revenue Refunding Bonds (State Transportation Commission - Senior Lien), Series 2024A
-
Stellar Bancorp, Inc. Declares Quarterly Dividend and New Share Repurchase Program
-
Sierra Madre Announces Francisco Correa as General Manager of La Guitarra Mine and Mill Complex, Grants Incentive Options
-
Cleantek Industries Inc. Announces First Quarter 2024 Results
-
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
-
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meet
-
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First
-
NMDP and CIBMTR to Present New, Promising Stem Cell Transplantation Trial Data using Mismatched, Unrelated Donors at 2024 ASCO Annual Meeting
-
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST
-
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
-
Timbercreek Financial Declares May 2024 Dividend
-
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
-
Canadian Premium Sand Inc. Announces Second Quarter 2024 Results